Visfatin and adiponectin as early markers of atherosclerosis in type 2 diabetes mellitus
IntroductionAs cardiovascular disease is the leading cause of mortality in type 2 diabetes mellitus, new markers for early detection and risk stratification of diabetic macroangiopathy and microangiopathy are highly desired. Adipocytokines were considered to lead to an increased risk of vascular com...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2013-01-01
|
| Series: | The Egyptian Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://www.esim.eg.net/article.asp?issn=1110-7782;year=2013;volume=25;issue=3;spage=143;epage=148;aulast=Zakaria |
| _version_ | 1819170155102470144 |
|---|---|
| author | Ibtissam Zakaria Mary N. Rizk Maha Rakha Amal Shehaby |
| author_facet | Ibtissam Zakaria Mary N. Rizk Maha Rakha Amal Shehaby |
| author_sort | Ibtissam Zakaria |
| collection | DOAJ |
| description | IntroductionAs cardiovascular disease is the leading cause of mortality in type 2 diabetes mellitus, new markers for early detection and risk stratification of diabetic macroangiopathy and microangiopathy are highly desired. Adipocytokines were considered to lead to an increased risk of vascular complications in patients with type 2 diabetes by modulating vascular function and affecting the inflammatory process, thus enhancing atherosclerosis. Two of these were of particular interest, namely, visfatin and adiponectin.
AimThe aim of this study was to evaluate serum visfatin, serum, and urinary adiponectin as early, sensitive surrogate markers of vascular atherosclerosis. We also correlated the levels of these markers to the degree of carotid intimal medial thickness (reflecting the atherosclerotic burden) in type 2 diabetic patients.
Results Sixty diabetic patients were subdivided into two groups: group I (30 patients with carotid atherosclerosis as assessed by carotid Doppler) and group II (30 patients without carotid atherosclerosis). Twenty healthy volunteers participated as controls. Serum visfatin as well as serum and urinary adiponectin were assessed in all the study groups. We found significantly higher levels of serum visfatin among diabetics compared with the control group. Visfatin was also significantly higher in group I diabetics with atherosclerosis than those without (P<0.05). Similarly, urinary adiponectin was significantly higher in group I than in group II and in diabetics than in the control group. Serum adiponectin was higher in the control group than both the study groups. Using a regression model, visfatin proved to be the only significant predictor in the model (β=0.03, P<0.001). In fact, visfatin alone proved significant, explaining 63% of the variability in carotid intima-media thickness (P<0.001).
Conclusion Serum visfatin is highly correlated with macrovascular complications in diabetic patients. Serum visfatin may emerge as a valuable and cheaper surrogate marker for the prediction of prevalent macrovascular complications in a type 2 diabetic population. It is a novel and easy-to-obtain method for the clinical assessment of vascular stress and cardiovascular disease risk in type 2 diabetes. Future prospective studies are needed to confirm our Results . |
| first_indexed | 2024-12-22T19:30:54Z |
| format | Article |
| id | doaj.art-cc3b8b58b2ca40d2b819b737ff918b73 |
| institution | Directory Open Access Journal |
| issn | 1110-7782 2090-9098 |
| language | English |
| last_indexed | 2024-12-22T19:30:54Z |
| publishDate | 2013-01-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | The Egyptian Journal of Internal Medicine |
| spelling | doaj.art-cc3b8b58b2ca40d2b819b737ff918b732022-12-21T18:15:07ZengSpringerOpenThe Egyptian Journal of Internal Medicine1110-77822090-90982013-01-0125314314810.7123/01.EJIM.0000433121.61723.90Visfatin and adiponectin as early markers of atherosclerosis in type 2 diabetes mellitusIbtissam ZakariaMary N. RizkMaha RakhaAmal ShehabyIntroductionAs cardiovascular disease is the leading cause of mortality in type 2 diabetes mellitus, new markers for early detection and risk stratification of diabetic macroangiopathy and microangiopathy are highly desired. Adipocytokines were considered to lead to an increased risk of vascular complications in patients with type 2 diabetes by modulating vascular function and affecting the inflammatory process, thus enhancing atherosclerosis. Two of these were of particular interest, namely, visfatin and adiponectin. AimThe aim of this study was to evaluate serum visfatin, serum, and urinary adiponectin as early, sensitive surrogate markers of vascular atherosclerosis. We also correlated the levels of these markers to the degree of carotid intimal medial thickness (reflecting the atherosclerotic burden) in type 2 diabetic patients. Results Sixty diabetic patients were subdivided into two groups: group I (30 patients with carotid atherosclerosis as assessed by carotid Doppler) and group II (30 patients without carotid atherosclerosis). Twenty healthy volunteers participated as controls. Serum visfatin as well as serum and urinary adiponectin were assessed in all the study groups. We found significantly higher levels of serum visfatin among diabetics compared with the control group. Visfatin was also significantly higher in group I diabetics with atherosclerosis than those without (P<0.05). Similarly, urinary adiponectin was significantly higher in group I than in group II and in diabetics than in the control group. Serum adiponectin was higher in the control group than both the study groups. Using a regression model, visfatin proved to be the only significant predictor in the model (β=0.03, P<0.001). In fact, visfatin alone proved significant, explaining 63% of the variability in carotid intima-media thickness (P<0.001). Conclusion Serum visfatin is highly correlated with macrovascular complications in diabetic patients. Serum visfatin may emerge as a valuable and cheaper surrogate marker for the prediction of prevalent macrovascular complications in a type 2 diabetic population. It is a novel and easy-to-obtain method for the clinical assessment of vascular stress and cardiovascular disease risk in type 2 diabetes. Future prospective studies are needed to confirm our Results .http://www.esim.eg.net/article.asp?issn=1110-7782;year=2013;volume=25;issue=3;spage=143;epage=148;aulast=Zakariaatherosclerosis, type 2 diabetes mellitus, visfatin |
| spellingShingle | Ibtissam Zakaria Mary N. Rizk Maha Rakha Amal Shehaby Visfatin and adiponectin as early markers of atherosclerosis in type 2 diabetes mellitus The Egyptian Journal of Internal Medicine atherosclerosis, type 2 diabetes mellitus, visfatin |
| title | Visfatin and adiponectin as early markers of atherosclerosis in type 2 diabetes mellitus |
| title_full | Visfatin and adiponectin as early markers of atherosclerosis in type 2 diabetes mellitus |
| title_fullStr | Visfatin and adiponectin as early markers of atherosclerosis in type 2 diabetes mellitus |
| title_full_unstemmed | Visfatin and adiponectin as early markers of atherosclerosis in type 2 diabetes mellitus |
| title_short | Visfatin and adiponectin as early markers of atherosclerosis in type 2 diabetes mellitus |
| title_sort | visfatin and adiponectin as early markers of atherosclerosis in type 2 diabetes mellitus |
| topic | atherosclerosis, type 2 diabetes mellitus, visfatin |
| url | http://www.esim.eg.net/article.asp?issn=1110-7782;year=2013;volume=25;issue=3;spage=143;epage=148;aulast=Zakaria |
| work_keys_str_mv | AT ibtissamzakaria visfatinandadiponectinasearlymarkersofatherosclerosisintype2diabetesmellitus AT marynrizk visfatinandadiponectinasearlymarkersofatherosclerosisintype2diabetesmellitus AT maharakha visfatinandadiponectinasearlymarkersofatherosclerosisintype2diabetesmellitus AT amalshehaby visfatinandadiponectinasearlymarkersofatherosclerosisintype2diabetesmellitus |